Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Ipilimumab ± radiation therapy in men with mCRPC

Final data have just been reported on the results of a Phase I/II study of treatment with ipilimumab as monotherapy and in combination with radiotherapy in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE ..

Small, Phase I combo trial suggests 3-year overall survival in men with mCRPC

A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …

Problems with enrollment into ongoing Phase III trials of new drugs for men with mCRPC?

Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer? … READ MORE …

Two new drugs recommended for approval in Europe

Two drugs already approved in the US that either have been or may be used in the treatment of prostate cancer have now been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). … READ MORE …

US FDA approves ipilimumab

The U.S. Food & Drug Administration today approved ipilimumab (brand name  Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer). … READ MORE …